表达猪繁殖与呼吸综合征病毒GP5蛋白基因重组犬2型腺病毒的构建及鉴定

为构建表达猪繁殖与呼吸综合征病毒(PRRSV)GP5蛋白的重组犬2型腺病毒(CAV-2),本研究将PRRSV GP5蛋白基因表达盒连接于E3区部分缺失的CAV-2全基因组重组质粒pPolyⅡ-CAV-2中,构建重组质粒pPoly-Ⅱ-CAV-2-GP5。并采用PmeⅠ和AscⅠ双酶切和脂质体介导法,将其转染MDCK细胞,获得重组病毒rCAV-2-GP5,经酶切鉴定显示该重组病毒含有目的基因。经RT-PCR检测表明,rCAV-2-GP5能够转录相应GP5蛋白基因mRNA;western blot检测证实GP5蛋白在MDCK细胞中得到表达。体外连续传30代检测表明,rCAV-2-GP5具有良好的遗传稳定性。本实验为PRRSV新型疫苗的研制奠定了基础。     

猪繁殖与呼吸综合征病毒GP5蛋白-重组犬1型腺病毒构建及在猪体内免疫特性

本试验根据猪繁殖与呼吸综合征病毒(PRRSV)基因组GP5蛋白的免疫原性,将PRRSV河北分离株GP5基因的表达盒克隆到犬1型腺病毒的感染性基因组的复制非必需区内,转染MDCK细胞,获得了重组病毒,免疫新生仔猪,分别在免疫后0～12周采集血清,通过ELISA检测证明,猪体同时产生了针对犬1型腺病毒和PRRSVGP5的抗体.说明GP5-重组犬1型腺病毒具有作为蓝耳病疫苗的潜力.     

Protective immunity induced by a recombinant pseudorabies virus expressing the GP5 of porcine reproductive and respiratory syndrome virus in piglets

Pseudorabies virus (PRV) has been developed as a vaccine vector for expressing foreign immunogens. Porcine reproductive and respiratory syndrome (PRRS), caused by porcine reproductive and respiratory syndrome virus (PRRSV), continues to be a major problem to the pork industry worldwide. Many vaccine strategies have been developed to control the disease but most of them turn out to be unsuccessful. The objective of this research was to explore the feasibility of PRV-based vector vaccine in protection against PRRSV. A live attenuated vaccine-based PRV recombinant expressing the envelope protein GP5 of PRRSV was generated using recombinant DNA techniques. The Bartha-K61-derived recombinant virus, named rPRV-GP5, was shown to express PRRSV GP5 efficiently. Sixteen healthy piglets were assigned to one of four groups (one to four, four pigs per group). Animals in Groups 1 and 2 were each inoculated intramuscularly and intranasally with 10(7.0) PFU of rPRV-GP5 and its parent Bartha-K61, respectively; Group 3 were vaccinated intramuscularly with one-dose of PRRS inactivated vaccine; Group 4 was served as non-vaccinated control. One month later, all animals were all challenged with 10(6.5) TCID(50) of virulent PRRSV CH-1a. All animals in Groups 1 and 3 remained clinically healthy before and after challenge, with only a short period of fever (no more than 41 degrees C and 3 days), mild and gradually improving lung and kidney lesions, and short-term viremia (2 and 3 week, respectively) in spite of no detectable anti-PRRSV antibody before challenge. On the other hand, all animals in the other two groups showed evident clinical signs with higher temperatures (more than 41 degrees C) after challenge, and severe lung, kidney and spleen lesions and extended viremia (4 weeks). The results indicate that the rPRV-GP5 is safe for vaccinates and able to confer significant protection against clinical disease and reduce pathogenic lesions induced by PRRSV challenge in vaccinated pigs.     

表达猪繁殖与呼吸综合征病毒ORF5/ORF6基因重组鸡痘病毒的构建与小鼠免疫试验

本试验构建了1株表达猪繁殖与呼吸综合征病毒(Porcine reproductive and respiratory syndrome virus,PRRSV)RF5/ORF6基因的重组鸡痘病毒,并进行了小鼠免疫实验,对其诱导BALB/c小鼠产生体液免疫和细胞免疫反应的能力进行了评价。结果表明,重组鸡痘病毒能够刺激免疫鼠产生特异性PRRSV ELISA抗体,促进特异性T淋巴细胞增殖。对免疫小鼠血清中细胞因子检测结果表明,IFN-γ的分泌显著提高。结果表明,所构建重组鸡痘病毒可以对小鼠起到良好的免疫效果,具有成为抗PRRSV感染新型疫苗的潜力。     

猪繁殖与呼吸综合征病毒M蛋白在重组牛痘病毒中的表达与鉴定

为重组表达猪繁殖与呼吸综合征病毒(PRRSV)M蛋白,本研究将RT-PCR获得的PRRSV CH-1a株M蛋白基因,克隆于pMD18-T载体中,经测序鉴定正确后,亚克隆至牛痘病毒重组转移质粒pSC11中,构建了转移重组质粒pSC11-PRRSV-M。将pSC11-PRRSV-M在脂质体的介导下转染WR株牛痘病毒感染的TK-143细胞,在含有X-gal的琼脂培养基上通过蓝斑筛选含有PRRSV M基因的重组病毒rWR-PRRSV-M。Western blot与IFA检测表明,重组病毒成功表达了PRRSV M蛋白,而且所表达的蛋白保持了良好的免疫原性。动物实验表明,rWR-PRRSV-M所表达的PRRSV M蛋白在免疫小鼠体内诱生了抗PRRSV的抗体。rWR-PRRSV-M的构建,为进一步探讨PRRSV M蛋白免疫原性提供了基础数据,也为PRRS重组活载体疫苗的研究奠定了基础。     

表达猪繁殖与呼吸综合征病毒CH-1a株核衣壳蛋白重组鸡痘病毒的构建

从含有猪繁殖与呼吸综合征病毒（PRRSV）核衣壳蛋白（N）的质粒扩增出N基因，构建禽痘病毒转移载体。该载体含有禽痘病毒早晚期启动子LP2EP2控制之下的PRRSVN基因、P11启动下的报告基因lacZ以及用于同源重组的禽痘病毒基因组的片段。在转移载体转染亲本病毒S—FPV-017感染的鸡胚成纤维细胞（CEF）之后，采用蓝色表型筛选的方法，筛选到表达N基因的重组病毒，并对其进行了6轮蚀斑纯化。PCR方法鉴定证明重组病毒的基因组中含有完整PRRSVN基因，间接免疫荧光试验证明了PRRSVN蛋白在重组病毒感染的CEF细胞中获得表达，本研究为猪繁殖与呼吸综合征非复制型疫苗的研制打下了基础。     

Immune responses in piglets infected with highly pathogenic porcine reproductive and respiratory syndrome virus

Porcine reproductive and respiratory syndrome virus (PRRSV) infection compromises the host's innate and adaptive immunity. The aim of this study was to investigate the immune responses of piglets infected with highly pathogenic (HP) PRRSV (HuN4 strain) with or without the immunization with CH-1R attenuated PRRSV vaccine. The response was evaluated for the clinical signs, pathological changes and virus load in immune organs, antibody responses and levels of serum IFN-γ, IL-4 and IL-10. The result showed that in comparison with the piglets received the immunization, the piglets infected with HP-PRRSV alone had the thymus atrophy, decreased serum levels of IL-4 and increased serum levels of IL-10 and INF-γ. These results suggest that elevated IL-10 levels at the early stage of the infection may enhance virus survival and delay the induction of protective immunity, while increased levels of IL-4 induce the effective immune responses and increase the animals' health status.     

Recombinant adenovirus expressing GP5 and M fusion proteins of porcine reproductive and respiratory syndrome virus induce both humoral and cell-mediated immune responses in mice

Porcine reproductive and respiratory syndrome virus (PRRSV) is one of the most important contagious agents of swine in the world. PRRSV infection poses a challenge to current vaccination strategies. In this study, three replication-defective adenovirus recombinants were developed as potential vaccine against PRRSV in a mouse model. Three groups of BALB/c mice (24 mice per group) were inoculated subcutaneously twice at 2-week intervals with the recombinants expressing PRRSV GP5 (rAd-GP5), M (rAd-M), and M-GP5 fusion protein (rAd-M-GP5). Two additional groups were injected with wild-type adenovirus (wtAd) or PBS as control. The results showed that the mice inoculated with recombinant adenoviruses developed PRRSV-specific antibodies, cellular immune response by 2 weeks post second inoculation. However, only mice immunized with recombinant adenovirus rAd-M-GP5 developed significantly higher titers of neutralizing antibodies to PRRSV and produced stronger lymphocyte proliferation responses compared to mice immunized with rAd-M or rAd-GP5 alone. It was also found that mice immunized with rAd-M-GP5 were primed for significant higher levels of anti-PRRSV CTL responses than mice immunized with rAd-M. Mice receiving rAd-GP5 also mounted PRRSV-specific response, but levels were lower. It suggested that the recombinant adenovirus expressing M-GP5 fusion protein might be an attractive candidate vaccine to be tested for preventing PRRSV infection.     

Biological responses to porcine respiratory and reproductive syndrome virus in pigs of two genetic populations

One hundred pigs from the NE Index Line (NEI) and 100 Hampshire-Duroc cross pigs (HD) were inoculated intranasally with porcine respiratory and reproductive syndrome virus (PRRSV 97-7895 strain) at 26 d of age to determine whether genetic variation in response to PRRSV exists. An uninfected littermate to each infected pig served as a control. Pigs were from 163 dams and 83 sires. Body weight and rectal temperature were recorded, and blood samples were drawn from each pig on d 0 before inoculation and on d 4, 7, and 14 after inoculation. Pigs were sacrificed on d 14. Lung and bronchial lymph nodes were collected, placed in optimal cutting temperature compound, and frozen at -80 degrees C. The presence of PRRSV in serum and in lung tissue and bronchial lymph nodes was determined by isolation in cell culture. The presence of antibodies in serum collected on d 14 was determined by a commercial ELISA test. Lung tissue was examined microscopically and scored for incidence and severity of lesions (score of 1 to 3; 1 = no or few lesions, and 3 = severe interstitial pneumonia). Data were analyzed with a mixed model that included random sire and dam effects. The interaction of line x treatment was significant (P < 0.001) for weight change and rectal temperature. Un-infected HD pigs gained 0.67 kg more from d 0 to 14 and averaged 0.32 degrees C higher rectal temperature than uninfected NEI pigs (P < 0.001), whereas infected NEI pigs gained 0.34 kg more and had -0.54 degrees C lower temperature than infected HD pigs (P < 0.001). Viremic titer (cell culture infectious dose 50%/mL) was greater (P < 0.05) in HD than NEI at d 4 (10(4.52) vs. 10(4.22)), 7 (10(4.47) vs. 10(3.99)), and 14 (10(3.49) vs. 10(3.23)). Viral titer loads in lung (P = 0.11) and bronchial lymph nodes tended (P = 0.07) to be greater in HD than NEI pigs. Antibody signal-to-positive (S/P) ELISA ratios in infected pigs ranged from 0.18 to 3.38, and 88% had levels > or = 0.40, which is the positive threshold for this ELISA. The S/P range in uninfected pigs was 0 to 1.11, and 99% had levels < or = 0.40. Mean S/P ratio for infected pigs was 0.23 units higher in HD than in NEI (P < 0.001). The HD pigs had a greater incidence of interstitial pneumonia and 0.65 higher mean lesion scores than NEI pigs (P < 0.001). In summary, responses of pigs of the two lines to infection with PRRSV differed, indicating that underlying genetic variation existed.     

高致病性猪繁殖与呼吸综合征病毒非结构蛋白NSP1对猪体免疫抑制作用

为了研究高致病性PRRSVNSP1蛋白的免疫作用,本研究将高致病性PRRSVNSP1重组腺病毒（rAd—NSP1）接种体外培养的猪肺泡细胞（PAM）,用实时荧光定量PCR和ELISA方法分别检测IFN-γ和IL-10水平,结果为rAd—NSP1接种PAM细胞72h后可显著降低细胞上清中IFN-γ的水平,而IL-10的含量显著提高。将rAd—NSP1接种无PRRSV感染的30日龄商品仔猪,分别检测其外周血液淋巴细胞增殖作用和IFN-γ与IL-10的水平,结果显示,NSP1可显著减低淋巴细胞增殖和IFN-7的表达,同时诱导产生较强的IL-10反应。采用无PRRSV感染的30日龄商品仔猪免疫猪瘟疫苗后1周接种rAd—NSP1,结果猪瘟抗体的水平明显低于wtAd组（P〈0．05）,证明高致病性PRRSVNSP1蛋白具有免疫抑制作用。     

PRRSV GP5蛋白在杆状病毒表达系统中的表达

参照包含猪繁殖与呼吸综合征病毒(porcine reproductive and respiratory syndrome virus,PRRSV) VR2332株完整ORF5基因的载体pMD18T-ORF5的核酸序列设计引物,扩增全长的PRRSV ORF5基因片段,同时以SOE-PCR技术扩增缺失信号肽和跨膜区的ORF5核酸片段ORF5NC,分别克隆至Bac-to-Bac杆状病毒表达系统的供体质粒pFastBac-HTA,获得重组转移载体pFastBacHTA-ORF5及截短表达的重组转移载体pFastBacHTA-ORF5NC。将供体质粒分别转化DH10Bac细胞,获得重组穿梭质粒,转染Sf9昆虫细胞,获得重组杆状病毒。SDS-PAGE和Western blot检测结果表明,在Sf9细胞中分别成功表达了全长的GP5重组蛋白和缺失信号肽、跨膜区的截短GP5重组蛋白。2种重组蛋白经纯化后,免疫小鼠制备抗血清,ELISA方法检测免疫GP5全长和截短重组蛋白的小鼠血清中抗体滴度分别为1∶800和1∶1 600,表明重组蛋白具有良好的免疫原性。本试验为进一步分析重组蛋白诱导中和抗体产生的能力以及为PRRSV基因工程亚单位疫苗的研究奠定基础。     

Serodiagnosis of porcine reproductive and respiratory syndrome virus infection with the use of glycoprotein 5 antigens

Glycoprotein 5 (GP5) of porcine reproductive and respiratory syndrome virus (PRRSV) has been studied extensively as a target for vaccine development. This study evaluated the serodiagnostic application of PRRSV GP5 by enzyme-linked immunosorbent assay (ELISA). Two immunodominant peptides (VR #1 and VR #2) and two neutralizing ectodomain-containing peptides (Ecto #1 and Ecto #2), as well as recombinant GP5 (rGP5) as a control, were prepared. Serum from unvaccinated pigs was screened for the antibodies that bind to these peptide and protein antigens. The results were compared with those from a commercially available diagnostic ELISA kit (HerdChek), which uses the nucleocapsid (N) protein as an antigen. Only VR #1+#2 showed a result statistically similar to that of N protein. Ecto #1 and Ecto #2 had a lower sensitivity than VR #1+#2 and rGP5. The peptides and rGP5 showed significant associations with the N protein (P < 0.05 or 0.01), which suggests that GP5 may also be a candidate serodiagnostic antigen. Since antibodies against GP5 persist much longer than those against the N protein, GP5 itself and some of its fragments are thought to be good targets for serodiagnosis. In addition, the presence of antibodies against the PRRSV structural antigens showed significant antigen-dependent differences.     

Differential immunity in pigs with high and low responses to porcine reproductive and respiratory syndrome virus infection

One hundred Hampshire x Duroc cross-bred pigs (HD) and 100 NE Index line (I) pigs were infected with porcine reproductive and respiratory syndrome (PRRS) virus and evaluated for resistance/susceptibility. Controls (100/line) were uninfected littermates to the infected pigs. Viremia, change in weight (WTdelta), and rectal temperature at 0, 4, 7, and 14 d postinfection were recorded. Lung, bronchial lymph node (BLN), and blood tissue were collected at necropsy (14 d postinfection). The first principal component from principal component analyses of all variables was used to rank the pigs for phenotypic response to PRRS virus. Low responders (low PRRS burden) had high WTdelta, low viremia, and few lung lesions; high responders (high PRRS burden) had low WTdelta, high viremia, and many lesions. The RNA was extracted from lung and BLN tissue of the 7 highest and 7 lowest responders per line and from each of their littermates. Expression of 11 innate and T helper 1 immune markers was evaluated with cDNA in a 2 x 2 x 2 factorial design. Significant upregulation in lung, lymph, or both of infected pigs relative to controls occurred for all but one gene. Expression differences were greater in HD than I pigs. Significant downregulation for certain immune genes in low pigs, relative to littermate controls, was detected in lung and BLN, particularly in line I. Serum levels of the immune cytokines affirmed the gene expression differences. High preinfection serum levels of IL 8 were significantly associated with PRRS virus-resistant, low pigs. After infection, low expression of interferon gamma in cDNA and in serum was also correlated with PRRS virus resistance. Important genetic associations were revealed for fine mapping of candidate genes for PRRS virus resistance and determining the causative alleles.     

高致病性猪繁殖与呼吸综合征病毒变异株主要囊膜糖蛋白GP5的遗传变异分析

为了探究高致病性猪蓝耳病病毒（HP-PRRSV）的遗传变异特征,本研究对GenBank中235株HP—PRRSV GP5序列的遗传进化、主要氨基酸基序、抗原性以及N-糖基化位点数量和位置的变异进行了分析。结果表明HP-PRRSV之间的同源性较高,与其他参考毒株相比,这些病毒处于一个相对独立的分支中,而且与经典疫苗株的亲缘关系较远。这有助于解释经典疫苗株对于HP—PRRSV为何起不到理想的免疫保护效果。在病毒的中和表位序列中存在着规律的点突变,同时抗原性比较显示HP-PRRSV与经典毒株之间存在着一定的差异。绝大多数的HP-PRRSV的N-糖基化位点在数量上多一个,而且位置要向羧基端平移2个氨基酸,从而使得中和表位两侧直接与糖链相连,可能会造成中和表位被糖侧链所遮掩,本研究由此推测减弱中和抗体对HP-PRRSV的有效识别,促进病毒逃避机体体液免疫。     

Immune responses and protection by vaccine and various vaccine adjuvant candidates to virulent porcine reproductive and respiratory syndrome virus

Various vaccine adjuvant candidates were assessed with the modified-live porcine reproductive and respiratory syndrome virus (MLV PRRSV) (Ingelvac PRRS MLV) vaccine. Their influence on humoral-mediated immune (HMI) and cell-mediated immune (CMI) responses as well as protection from virulent PRRSV challenge (MN-184) was evaluated. Ninety seronegative pigs were randomly divided into nine groups of 10 pigs. One group received MLV vaccine alone. Five groups received MLV vaccine with either bacterial endotoxin-derived adjuvant (ET), mixed open reading frame 5 (ORF5) peptides derived from various PRRSV isolates, porcine interferon alpha (IFNalpha), polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC), or porcine interleukin-12 (IL-12). One group did not receive MLV vaccine but was immunized with ORF5 peptides conjugated with cholera toxin (ORF5 peptide/CT). Two groups served as challenged and unchallenged non-vaccinated controls. Four-color flow cytometry was utilized to simultaneously identify three major porcine T-cell surface markers (CD4, CD8, and gammadelta TCR) and detect activation marker CD25 (alpha chain of IL-2 receptor) or intracellular IFNgamma. The MLV PRRSV vaccine alone successfully primed CD4(-)CD8(+)gammadelta- T-cells as demonstrated by a significant increase in %IFNgamma+ cells when live PRRSV was used as a recall antigen. Booster immunizations of mixed ORF5 peptides and co-administration of IL-12 with MLV PRRSV vaccine significantly enhanced IFNgamma expression by some T-cell subsets (CD4(-)CD8(+)gammadelta+ and CD4(-)CD8(-)gammadelta+ for mixed ORF5 peptides and CD4(+)CD8(+)gammadelta- and CD4(-)CD8(+)gammadelta+ for IL-12). All groups receiving MLV-vaccine with or without adjuvants had reduced lung lesions after challenge. The group immunized with only ORF5 peptide/CT did not have significant T-cell recall responses and was not protected from challenge. Expression of IFNgamma by several T-cell subsets correlated with reduced lung lesions and viremia, whereas expression of CD25 did not. Expression of surface CD25 did not correlate with IFNgamma production. PRRSV ELISA s/p ratio prior to challenge also correlated with reduced lung lesions and viremia. In conclusion, booster immunizations of the mixed ORF5 peptides and co-administration of IL-12 effectively enhanced the CMI response to MLV vaccine. However, neither adjuvant significantly contributed to reducing clinical effects when compared to MLV alone.     

Recombinant Kluyveromyces lactis expressing highly pathogenic porcine reproductive and respiratory syndrome virus GP5 elicits mucosal and cell-mediated immune responses in mice

Currently, killed-virus and modified-live porcine reproductive and respiratory syndrome virus (PRRSV) vaccines are used to control porcine reproductive and respiratory syndrome. However, both types of vaccines have inherent drawbacks; accordingly, the development of novel PRRSV vaccines is urgently needed. Previous studies have suggested that yeast possesses adjuvant activities, and it has been used as an expression vehicle to elicit immune responses to foreign antigens. In this report, recombinant Kluyveromyces lactis expressing GP5 of HP-PRRSV (Yeast-GP5) was generated and immune responses to this construct were analyzed in mice. Intestinal mucosal PRRSV-specific sIgA antibody and higher levels of IFN-γ in spleen CD4⁺ and CD8⁺ T cells were induced by oral administration of Yeast-GP5. Additionally, Yeast-GP5 administered subcutaneously evoked vigorous cell-mediated immunity, and PRRSV-specific lymphocyte proliferation and IFN-γ secretion were detected in the splenocytes of mice. These results suggest that Yeast-GP5 has the potential for use as a vaccine for PRRSV in the future.     

Immune responses of recombinant adenovirus co-expressing VP1 of foot-and-mouth disease virus and porcine interferon alpha in mice and guinea pigs

Foot-and-mouth disease (FMD) is a highly contagious and economically devastating vesicular disease of cloven-hoofed animals. In this study, we constructed and characterized the immune responses and vaccine efficacy conferred by the recombinant adenovirus co-expressing VP1 of FMDV and porcine interferon alpha as fusion protein (rAd-pIFNalpha-VP1). Six groups of female BALB/c mice each with 18 were inoculated subcutaneously twice 2-week intervals with the recombinant adenoviruses. The results showed that the levels of humoral and cell-mediated immune responses in the group inoculated with rAd-pIFNalpha-VP1 were significantly higher than those in the group inoculated with rAd-VP1+rAd-pIFNalpha (P<0.05). Then four groups of guinea pigs each with six were inoculated two times at 2-week intervals intramuscularly with rAd-pIFNalpha-VP1, commercial inactivated FMD vaccine, wild-type adenovirus (wtAd) or PBS, and the protective efficacy of rAd-pIFNalpha-VP1 was determined. The results indicated that all the guinea pigs vaccinated with rAd-pIFNalpha-VP1 as well as inactivated FMD vaccine were protected from FMDV challenge, even though the levels of neutralizing antibodies (1:32-1:40) of the animals vaccinated with rAd-pIFNalpha-VP1 was lower than that in the group inoculated with inactivated FMD vaccine (1:64-1:128). It demonstrated that the newly recombinant adenovirus rAd-pIFNalpha-VP1 might further be an attractive candidate vaccine for preventing FMDV infection in swine.     

Immune responses of swine following DNA immunization with plasmids encoding porcine reproductive and respiratory syndrome virus ORFs 5 and 7, and porcine IL-2 and IFNgamma

In the present study, five eukaryotic double-gene expression plasmids containing porcine reproductive and respiratory syndrome virus (PRRSV) ORF5 and ORF7 genes combined with cDNAs encoding porcine IFNgamma and IL-2 were constructed for evaluation as PRRSV vaccine candidates. After immunization and viral challenge, two of three pigs immunized with pIRESorf5/IFNgamma, one of three pigs immunized with pIRESorf5/IL-2 and one of three pigs immunized with pIRESorf7/IL-2 were protected from lung lesions that were present in other vaccinated and control animals. Virus replication was reduced but not completely prevented in organs of the DNA-vaccinated animals as compared to controls. Therefore, the porcine cytokines IFNgamma and IL-2, delivered in combination with ORF5 or ORF7, may improve the immune efficacy of DNA vaccines against PRRSV.     

表达猪瘟病毒E2蛋白重组猪繁殖与呼吸道综合征病毒的研究

为构建表达猪瘟病毒(CSFV)E2蛋白重组猪繁殖与呼吸道综合征病毒(PRRSV),本研究首先利用高致病性PRRSV弱毒疫苗HuN4-F112株的感染性分子克隆作为平台,构建了一个在nsp2区有缺失的感染性分子克隆,命名为pHuN4-F112-△480-620。以pHuN4-F112-△480-620作为载体,采用突变PCR的方法将CSFV的主要保护性抗原E2基因1 bp～9 99 bp,1 bp～600 bp,1 bp～330 bp及256 bp～330 bp基因片段分别插到nsp2中aa 480～aa 620位氨基酸缺失编码区域。结果显示,插入完整E2基因或较大E2基因片段的重组PRRSV cDNA质粒均未能拯救出病毒,只有插入较小的E2基因片段(256 bp～330 bp)的重组病毒cDNA质粒成功地拯救出了重组病毒rPRRSV-F112-E2(256-330),拯救的病毒能够在MARC-145细胞上引起明显的细胞病变,而且生长速度明显高于其亲本病毒,间接荧光检测表明该重组病毒能够表达外源基因。     

Genomic and antigenic variations of porcine reproductive and respiratory syndrome virus major envelope GP5 glycoprotein.

The objective of the present study was to evaluate the importance of genomic and antigenic variations which may have affected the major envelope glycoprotein GP5 of porcine reproductive and respiratory syndrome virus (PRRSV) isolates responsible for outbreaks in Quebec and Ontario, in comparison with the modified-live U.S. vaccine strain (MLV) and the European prototype strain from Lelystad (LV). Nucleotide sequence analyses of the open reading frame (ORF)5 genes showed that all of the isolates studied were heterogenous, amino acid (aa) identities varied from 88 to 99% with the MLV strain, and between 51 and 54% with the LV strain. The aa substitutions were randomly scattered across the protein, although one region between residues 26 and 39 was found to correspond to a hypervariable region which involved 0 to 3 potential N-glycosylation sites. The ORF5 encoded products of 5 of these isolates, including the MLV and LV strains, were expressed in E. coli as recombinant proteins fused to the glutathione S-transferase (GST) protein and used to raise hyperimmune anti-ORF5 sera in rabbits. The reactivity patterns of strain-specific hyperimmune anti-ORF5 sera and a panel of 4 monoclonal antibodies directed against the ORF5 gene product of the Quebec IAF-Klop strain of PRRSV, indicated that GP5 of field isolates also underwent antigenic variations. The data suggest that neutralizing epitopes, independent of conformation and glycosylation, are also associated with antigenic variability of the GP5 of PRRSV.